ECCO 2025

R&D

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.